Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus MPI INDIUM DTPA IN 111.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus MPI INDIUM DTPA IN 111.
CIS-MDP vs MPI INDIUM DTPA IN 111
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical